Genetic Signatures
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 11 June 2026
- Reported shorts
- 7K
- Shares on issue
- 227.139M
Genetic Signatures (GSS) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $14.5Mvs $15.9M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- NPAT
- −$14.0Mvs −$20.1M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.062T (source: Derived: trailing 12 months at year end)vs −$0.089 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −9.1%FY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Summary of FY26 Appendix 4E and Annual Report, 25 Aug 2026
Genetic Signatures reported FY2026 revenue of $14.8 million, down 6.7% from the prior year, while net loss narrowed 30.3% to $14.0 million. No dividends were paid or declared. The company completed a strategic review and restructuring, targeting annualised cost savings of up to $5 million from FY2027, and signed a ten-year supply agreement with a Danish hospital.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- 34.5%
- Operating margin
- −122.8%
- Net margin
- −96.9%
- FCF margin
- −61.0%
- ROE
- −32.6%
- ROA
- −30.1%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $9.1M
- Net debt / EBITDA
- n/a
- Current ratio
- 13.1×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $18.9M
- P/E
- n/a
- P/B
- 0.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $14.5M | $15.9M | $9.8M | $21.4M |
| Gross profit | $5.0M | $7.8M | $4.3M | $13.4M |
| Operating income | −$17.7M | −$18.5M | −$22.3M | −$14.7M |
| EBITDA | −$15.7M | −$16.1M | −$20.3M | −$12.5M |
| EBIT | −$17.7M | −$18.5M | −$22.3M | −$14.1M |
| Interest expense | n/a | n/a | n/a | $1.0K |
| Pretax income | −$14.0M | −$20.1M | −$17.9M | −$14.1M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$14.0M | −$20.1M | −$17.9M | −$14.1M |
| Net interest income | $939.0K | $1.5M | $469.0K | $542.0K |
| EPS basic | −$0.062T (source: Derived: trailing 12 months at year end) | −$0.089 | −$0.11 | −$0.096 |
| EPS diluted | −$0.062T (source: Derived: trailing 12 months at year end) | −$0.089 | −$0.11 | −$0.096 |
| Shares | 227.1M | 227.1M | 215.3M | 146.8M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report8 Oct 2026via asx_announcements
- FY26 Appendix 4E and Annual ReportAnnual Results25 Aug 2026via asx_announcements
- FY 26 Annual Results and Investor Webinar NotificationFinancial Report24 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- 1H FY26 Appendix 4D and Half Year ReportHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report20 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report21 Oct 2025via asx_announcements
- FY25 Appendix 4E and Annual ReportAnnual Results25 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report22 Jul 2025via asx_announcements
Showing 10 of 19 reports